HOPKINTON, Mass. -- Caliper Life Sciences Inc., which makes technologies used for drug development, said Monday its third-quarter loss narrowed on lower costs and charges.

For the period ended Sept. 30, Caliper reported lost $3.4 million, or 7 cents per share, compared with a loss of $5.4 million, or 11 cents per share, in the same period last year. Revenue fell 5 percent to $32.2 million from $34 million.

Meanwhile, costs and expenses fell 9 percent to $35.3 million on lower restructuring charges and research and development costs.

Looking ahead, the company said it expects fourth-quarter revenue between $34.5 million and $36.5 million. It expects full-year revenue between $127 million and $129 million.

Shares of Caliper rose 40 cents, or 19 percent, to $2.55 in afternoon trading. The stock has traded between 63 cents and $3.02 over the last 52 weeks.

Join the discussion

The Miami Herald is pleased to provide this opportunity to share information, experiences and observations about what's in the news. Some of the comments may be reprinted elsewhere in the site or in the newspaper. We encourage lively, open debate on the issues of the day, and ask that you refrain from profanity, hate speech, personal comments and remarks that are off point. In order to post comments, you must be a registered user of MiamiHerald.com. Your username will show along with the comments you post. Thank you for taking the time to offer your thoughts.

     Showing: Oldest first Newest first Most-recommended first Least-recommended first

@Nyx.AuthorDisplayName@ wrote on @Nyx.PostedAtTime@:

@Nyx.repliedToText@

@Nyx.replyAnswerText@

Reply to this Comment @Nyx.Recommender@ @Nyx.AbuseReporter@